Search

Your search keyword '"Libertini M"' showing total 123 results
Start Over Author "Libertini M"
123 results on '"Libertini M"'

1. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience

Author

Boccaccino, A., Borelli, B., Intini, R., Antista, M., Bensi, M., Rossini, D., Passardi, A., Tamberi, S., Giampieri, R., Antonuzzo, L., Noto, L., Roviello, G., Zichi, C., Salati, M., Puccini, A., Noto, C., Parisi, A., Rihawi, K., Persano, M., Crespi, V., Libertini, M., Giordano, M., Moretto, R., Lonardi, S., and Cremolini, C.

Published
2022
Full Text
View/download PDF

2. Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses

Author

Palassini, E., Mir, O., Grignani, G., Vincenzi, B., Gelderblom, H., Sebio, A., Valverde, C., Baldi, G. G., Brunello, A., Cardellino, G. G., Marrari, A., Badalamenti, G., Martin-Broto, J., Ferraresi, V., Libertini, M., Turano, S., Gataa, I., Collini, P., Tos, A. P. Dei, Gennaro, M., Bini, F., Provenzano, S., Vullo, S. Lo, Mariani, L., Le Cesne, A., and Casali, P. G.

Published
2022
Full Text
View/download PDF

3. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies

Author

Marmorino, F., Rossini, D., Lonardi, S., Moretto, R., Zucchelli, G., Aprile, G., Dell’Aquila, E., Ratti, M., Bergamo, F., Masi, G., Urbano, F., Ronzoni, M., Libertini, M., Borelli, B., Randon, G., Buonadonna, A., Allegrini, G., Pella, N., Ricci, V., Boccaccino, A., Latiano, T.P., Cordio, S., Passardi, A., Tamburini, E., Boni, L., Falcone, A., and Cremolini, C.

Published
2019
Full Text
View/download PDF

4. Supplementary Figure 1 from Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-à-vis Temozolomide and Antiangiogenics

Author

Stacchiotti, S., primary, Tortoreto, M., primary, Bozzi, F., primary, Tamborini, E., primary, Morosi, C., primary, Messina, A., primary, Libertini, M., primary, Palassini, E., primary, Cominetti, D., primary, Negri, T., primary, Gronchi, A., primary, Pilotti, S., primary, Zaffaroni, N., primary, and Casali, P.G., primary

Published
2023
Full Text
View/download PDF

5. Supplementary Figure 3 from Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-à-vis Temozolomide and Antiangiogenics

Author

Stacchiotti, S., primary, Tortoreto, M., primary, Bozzi, F., primary, Tamborini, E., primary, Morosi, C., primary, Messina, A., primary, Libertini, M., primary, Palassini, E., primary, Cominetti, D., primary, Negri, T., primary, Gronchi, A., primary, Pilotti, S., primary, Zaffaroni, N., primary, and Casali, P.G., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure 2 from Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-à-vis Temozolomide and Antiangiogenics

Author

Stacchiotti, S., primary, Tortoreto, M., primary, Bozzi, F., primary, Tamborini, E., primary, Morosi, C., primary, Messina, A., primary, Libertini, M., primary, Palassini, E., primary, Cominetti, D., primary, Negri, T., primary, Gronchi, A., primary, Pilotti, S., primary, Zaffaroni, N., primary, and Casali, P.G., primary

Published
2023
Full Text
View/download PDF

7. Come cambia il dottorato di ricerca

Author

Carloni, E, Cortese, F, Giglioni, F, Libertini, M, Marra, A, Mattarella, BG, Moscati, R, Rivellini, G, Vella, F, Vesperini, G, Ramajoli, M, Carloni, E, Cortese, F, Giglioni, F, Libertini, M, Marra, A, Mattarella, BG, Moscati, R, Rivellini, G, Vella, F, Vesperini, G, and Ramajoli, M

Published
2023

8. Introduzione

Author

Carloni, E, Cortese, F, Giglioni, F, Libertini, M, Marra, A, Mattarella, BG, Moscati, R, Rivellini, G, Vella, F, Vesperini, G, Ramajoli M, Ramajoli, M, Marra A., Carloni, E, Cortese, F, Giglioni, F, Libertini, M, Marra, A, Mattarella, BG, Moscati, R, Rivellini, G, Vella, F, Vesperini, G, Ramajoli M, Ramajoli, M, and Marra A.

Published
2023

10. L'uguaglianza formale e sostanziale tra libertà e giustizia 'contrattuale'

Author

Albanese, A, Alpa, G, Barba, A, Barcellona, M, Benatti, F, Castronovo, C, Gentili, A, Irti, N, Libertini, M, Nicolussi, A, Salvi, C, Scognamiglio, C, Cesaro, E, de Luca Tamajo, R, Fiorillo, L, Lambertucci, P, Maresca, A, Rusciano, M, Santoni, F, Santoro Passarelli, G., Albanese, Antonio, Antonio Albanese (ORCID:0000-0002-3897-5810), Albanese, A, Alpa, G, Barba, A, Barcellona, M, Benatti, F, Castronovo, C, Gentili, A, Irti, N, Libertini, M, Nicolussi, A, Salvi, C, Scognamiglio, C, Cesaro, E, de Luca Tamajo, R, Fiorillo, L, Lambertucci, P, Maresca, A, Rusciano, M, Santoni, F, Santoro Passarelli, G., Albanese, Antonio, and Antonio Albanese (ORCID:0000-0002-3897-5810)

Abstract

The essay aims to verify if and in what way the contractual freedom can be reconciled with the judicial review on the justice of the contract. From this perspective, the legal system cannot replace the will of the contracting parties, imposing or prohibiting a specific negotiating regulation deemed "just" or "unfair" a priori, but it can disapprove of those agreements that ex post are illegally imposed by the stronger party. According to this logic, judicial control over private autonomy is admitted only in cases where any inequity reflects inequalities between the parties as one of them has wrongly taken advantage of it. However, given that some disparity between the contracting parties is found in all exchanges, a rebalancing intervention cannot be general nor be carried out indiscriminately, but is legitimized only in the presence of certain normative situations that justify it rationally. In these cases, contractual justice takes place in the form of protection of the weaker contractual party with respect to abuses of the stronger one that prevented him from effectively exercising his autonomy.

Published
2022

12. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

Author

Pinato, DJ, Aguilar-Company, J, Ferrante, D, Hanbury, G, Bower, M, Salazar, R, Mirallas, O, Sureda, A, Plaja, A, Cucurull, M, Mesia, R, Townsend, S, Jackson, A, Dalla Pria, A, Newsom-Davis, T, Handford, J, Sita-Lumsden, A, Apthorp, E, Vincenzi, B, Bertuzzi, A, Brunet, J, Lambertini, M, Maluquer, C, Pedrazzoli, P, Biello, F, Sinclair, A, Bawany, S, Khalique, S, Rossi, S, Rogers, L, Murphy, C, Belessiotis, K, Carmona-Garcia, MC, Sharkey, R, Garcia-Illescas, D, Rizzo, G, Perachino, M, Saoudi-Gonzalez, N, Doonga, K, Fox, L, Roldan, E, Gaidano, G, Ruiz-Camps, I, Bruna, R, Patriarca, A, Martinez-Vila, C, Cantini, L, Zambelli, A, Giusti, R, Mazzoni, F, Caliman, E, Santoro, A, Grosso, F, Parisi, A, Queirolo, P, Aujayeb, A, Rimassa, L, Prat, A, Tucci, M, Libertini, M, Grisanti, S, Mukherjee, U, Diamantis, N, Fusco, V, Generali, D, Provenzano, S, Gennari, A, Tabernero, J, and Cortellini, A

Abstract

Background The omicron (B.1.1.529) variant of SARS-CoV-2 is highly transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due to COVID-19 during the omicron outbreak compared with the prevaccination period and alpha (B.1.1.7) and delta (B.1.617.2) waves in patients with cancer in Europe. Methods In this retrospective analysis of the multicentre OnCovid Registry study, we recruited patients aged 18 years or older with laboratory-confirmed diagnosis of SARS-CoV-2, who had a history of solid or haematological malignancy that was either active or in remission. Patient were recruited from 37 oncology centres from UK, Italy, Spain, France, Belgium, and Germany. Participants were followed up from COVID-19 diagnosis until death or loss to follow-up, while being treated as per standard of care. For this analysis, we excluded data from centres that did not actively enter new data after March 1, 2021 (in France, Germany, and Belgium). We compared measures of COVID-19 morbidity, which were complications from COVID-19, hospitalisation due to COVID-19, and requirement of supplemental oxygen and COVID-19-specific therapies, and COVID-19 mortality across three time periods designated as the prevaccination (Feb 27 to Nov 30, 2020), alpha-delta (Dec 1, 2020, to Dec 14, 2021), and omicron (Dec 15, 2021, to Jan 31, 2022) phases. We assessed all-cause case-fatality rates at 14 days and 28 days after diagnosis of COVID-19 overall and in unvaccinated and fully vaccinated patients and in those who received a booster dose, after adjusting for country of origin, sex, age, comorbidities, tumour type, stage, and status, and receipt of systemic anti-cancer therapy. This study is registered with ClinicalTrials.gov, NCT04393974, and is ongoing. Findings As of Feb 4, 2022 (database lock), the registry included 3820 patients who had been diagnosed with COVID-19 between Feb 27, 2020, and Jan 31, 2022. 3473 patients were eligible for inclusion (1640 [47.4%] were women and 1822 [52.6%] were men, with a median age of 68 years [IQR 57-77]). 2033 (58.5%) of 3473 were diagnosed during the prevaccination phase, 1075 (31.0%) during the alpha-delta phase, and 365 (10.5%) during the omicron phase. Among patients diagnosed during the omicron phase, 113 (33.3%) of 339 were fully vaccinated and 165 (48.7%) were boosted, whereas among those diagnosed during the alpha-delta phase, 152 (16.6%) of 915 were fully vaccinated and 21 (2.3%) were boosted. Compared with patients diagnosed during the prevaccination period, those who were diagnosed during the omicron phase had lower case-fatality rates at 14 days (adjusted odds ratio [OR] 0.32 [95% CI 0.19-0.61) and 28 days (0.34 [0.16-0.79]), complications due to COVID-19 (0.26 [0.17-0.46]), and hospitalisation due to COVID-19 (0.17 [0.09-0.32]), and had less requirements for COVID-19-specific therapy (0.22 [0.15-0.34]) and oxygen therapy (0.24 [0.14-0.43]) than did those diagnosed during the alpha-delta phase. Unvaccinated patients diagnosed during the omicron phase had similar crude case-fatality rates at 14 days (ten [25%] of 40 patients vs 114 [17%] of 656) and at 28 days (11 [27%] of 40 vs 184 [28%] of 656) and similar rates of hospitalisation due to COVID-19 (18 [43%] of 42 vs 266 [41%] of 652) and complications from COVID-19 (13 [31%] of 42 vs 237 [36%] of 659) as those diagnosed during the alpha-delta phase. Interpretation Despite time-dependent improvements in outcomes reported in the omicron phase compared with the earlier phases of the pandemic, patients with cancer remain highly susceptible to SARS-CoV-2 if they are not vaccinated against SARS-CoV-2. Our findings support universal vaccination of patients with cancer as a protective measure against morbidity and mortality from COVID-19. Copyright (C) 2022. Published by Elsevier Ltd. All rights reserved.

Published
2022

15. Clinical portrait of the SARS-Cov-2 epidemic in European cancer patients

Author

Pinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng C, Salazar R, Bertuzzi A, Brunet J, Mesia R, Segui E, Biello F, Generali D, Grisanti S, Rizzo G, Libertini M, Maconi A, Harbeck N, Vincenzi B, Bertulli R, Ottaviani D, Carbo A, Bruna R, Benafif S, Marrari A, Wuerstlein R, Carmona-Garcia MC, Chopra N, Tondini C, Mirallas O, Tovazzi V, Betti M, Provenzano S, Fotia V, Cruz CA, Dalla Pria A, D'Avanzo F, Evans JS, Saoudi-Gonzalez N, Felip E, Galazi M, Garcia-Fructuoso I, Lee AJX, Newsom-Davis T, Patriarca A, Garcia-Illescas D, Reyes R, Dileo P, Sharkey R, Wong YNS, Ferrante D, Marco-Hernandez J, Sureda A, Maluquer C, Ruiz-Camps I, Gaidano G, Rimassa L, Chiudinelli L, Izuzquiza M, Cabirta A, Franchi M, Santoro A, Prat A, Tabernero J, Gennari A, Wellcome Trust, and Cancer Treatment & Research Trust

Subjects
1112 Oncology and Carcinogenesis
Abstract

The SARS-Cov-2 pandemic significantly impacted on oncology practice across the globe. There is uncertainty as to the contribution of patients' demographics and oncological features on severity and mortality from Covid-19 and little guidance as to the role of anti-cancer and anti-Covid-19 therapy in this population. In a multi-center study of 890 cancer patients with confirmed Covid-19 we demonstrated a worsening gradient of mortality from breast cancer to haematological malignancies and showed that male gender, older age, and number of co-morbidities identifies a subset of patients with significantly worse mortality rates from Covid-19. Provision of chemotherapy, targeted therapy and immunotherapy did not worsen mortality. Exposure to antimalarials was associated with improved mortality rates independent of baseline prognostic factors. This study highlights the clinical utility of demographic factors for individualized risk-stratification of patients and support further research into emerging anti-Covid-19 therapeutics in SARS-Cov-2 infected cancer patients.

Published
2020

16. 318O Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients

Author

Pinato, D.J., primary, Zambelli, A., additional, Bertuzzi, A., additional, Marrari, A., additional, Saoudi-Gonzalez, N., additional, Mirallas, O., additional, Galazi, M., additional, Generali, D., additional, Grisanti, S., additional, Tondini, C., additional, Prat, A., additional, Tabernero, J., additional, Mesia, R., additional, Salazar, R., additional, Sureda, A., additional, Franchi, M., additional, Chiudinelli, L., additional, Illescas, D.G., additional, Libertini, M., additional, and Gennari, A., additional

Published
2020
Full Text
View/download PDF

17. 447P Long term survival with regorafenib: REALITY (real life in Italy) trial - A GISCAD Study

Author

Lai, E., primary, Cremolini, C., additional, Puzzoni, M., additional, Bergamo, F., additional, Zucchelli, G., additional, Libertini, M., additional, Dettori, M., additional, Banzi, M., additional, Boccaccino, A., additional, Cinieri, S., additional, Cavo, A., additional, Piacentini, G., additional, Andreozzi, F., additional, Banna, G.L., additional, Nappo, F., additional, Iachetta, F., additional, Rota, S., additional, Conca, V., additional, Zaniboni, A., additional, and Scartozzi, M., additional

Published
2020
Full Text
View/download PDF

18. Il controllo congiunto nelle società a partecipazione pubblica prevalente

Author

Costi, R, Clarich, M, Ibba, C, Libertini, M., Marasà, G., Dugato, M, Sanna, V, Guerrera, F, Stella Richter, M, Racugno, G, Serra, A, Torchia, L, Rivolta, GCM, Cian, M, Donativi, V, Demuro, I, Montalenti, P, Angelici, C, Carlo Ibba, Demuro, Ivan, Demuro, I (ORCID:0000-0002-7471-1353), Costi, R, Clarich, M, Ibba, C, Libertini, M., Marasà, G., Dugato, M, Sanna, V, Guerrera, F, Stella Richter, M, Racugno, G, Serra, A, Torchia, L, Rivolta, GCM, Cian, M, Donativi, V, Demuro, I, Montalenti, P, Angelici, C, Carlo Ibba, Demuro, Ivan, and Demuro, I (ORCID:0000-0002-7471-1353)

Abstract

Il saggio analizza le problematiche relativi alla configurazione del controllo congiunto nelle società a partecipazione pubblica prevalente. Si tiene conto degli orientamenti interpretativi derivanti dalle pronunce della Corte dei conti

Published
2019

19. Prognostic and predictive role of body mass index (BMI) in metastatic colorectal cancer (mCRC): A pooled analisys of TRIBE and TRIBE-2 studies by GONO

Author

Dell’Aquila, E., primary, Rossini, D., additional, Stellato, M., additional, Bergamo, F., additional, Aprile, G., additional, Morano, F., additional, Intini, R., additional, Fea, E., additional, Ronzoni, M., additional, Libertini, M., additional, Buonadonna, A., additional, Fanchini, L., additional, Marcucci, L., additional, Maiello, E., additional, Marmorino, F., additional, Boccaccino, A., additional, Cordio, S., additional, Masi, G., additional, Falcone, A., additional, and Santini, D., additional

Published
2019
Full Text
View/download PDF

20. The role of adjuvant therapy in resectable SBA: A different clinicians attitude with a relevant impact on outcome

Author

Orsi, G., primary, Andrikou, K., additional, Bergamo, F., additional, Nappo, F., additional, Manai, C., additional, Passardi, A., additional, Puzzoni, M., additional, Vallarelli, S., additional, Libertini, M., additional, Riggi, M.L., additional, Pugliese, G., additional, Zaniboni, A., additional, Schirripa, M., additional, Procaccio, L., additional, Silvestris, N., additional, Scartozzi, M., additional, Casadei Gardini, A., additional, Zagonel, V., additional, and Cascinu, S., additional

Published
2018
Full Text
View/download PDF

24. Della disciplina della concorrenza

Author

Libertini, M. and Genovese, Anna

Subjects
patti di non concorrenza, inibitoria della concorrenza sleale, obblighi dell'impresa monopolista legale, concorrenza sleale, risarcimento del danno da concorrenza sleale
Published
2014

25. La tutela del terzo nella esecuzione per consegna o rilascio su titiolo esecutivo notarile

Author

ACONE, M, ANDOLINA, IA, AULETTA, F, BALENA, G, BASILICO, G, CAVALLINI, C, CAVALLONE, B, CHIZZINI, A, COMOGLIO, LP, CORSINI, F, DI CARLO, G, DITTRICH, L, GIORGETTI, M, GIOVANNUCCI ORLANDI, C, GIUSSANI, A, GUARNIERI, G, IMPAGNATIELLO, G, LA CHINA, S, LANFRANCHI, L, MENCHINI, S, PETRELLA, V, PICARDI, N, RUFFINI, G, SANDULLI, P, SOTGIU, N, TRISORIO LIUZZI, G, VALENTINI, S, CAPPONI, B, GRAZIOSI, A, IANNICELLI, L, MACCARRONE, R, NERI, A, PROTO PISANI, A, CORDOPATRI, F, LAZZARA, G, TESORIERE, G, VACCARELLA, R, VELLANI, M, CHIARLONI, S, COSTANTINO, G, DI FABIO, M, PAGNI, I, SASSANI, B, SCALA, A, BERNARDINI, P, BERTOLDI, V, BOCCAGNA, S, BORGHESI, D, BOVE, M, CANALE, G, CARPI, F, CONSOLO, C, DANOVI, F, FAZZALARI, E, GROSSI, D, LUBRANO, F, MARINELLI, M, MARINUCCI, E, NELA, PL, PICOZZA, E, RAVIDÀ, F, RICCI, EF, RICCI, GF, RIGHETTI, E, SEATZU, F, TAMPONI, M, TAVORMINA, V, VERDE, Giuseppe, VIGORITI, V, ZUCCONI GALLI FONSECA, E, BRIGUGLIO, A, CARRATTA, A, DALFINO, D, GRADI, M, MARTINO, R, OLIVIERI, G, PICCININNI, L, POLI, R, RASCIO, N, RINALDI, S, RUGGERI, E, TROIANO, R, VITRÒ, V, CIPRIANI, F, D’ALESSIO, A, DALMOTTO, E, DELLA PIETRA G, LUISO, FP, NARDO, GN, PROSPERETTI, G, QUERZOLA, L, TOMMASEO, F, VULLO, E, BONGIORNO, G, CORRADO, C, DE SANTIS, F, FABIANI, M, FINOCCHIARO, G, FARINA, P, LIGUORI, G, MANCUSO, C, MONTANARI, M, NICÒTINA, G, ORIANI ,R, RECCHIONI, S, SALETTI, A, DE ROBERTO, A, FANTOZZI, A, ODORISIO, E, SCOCA, F. G, VIOLANTE, V, LIBERTINI, M, MURRA, R, RENZETTI, F, RESTA, D, SCIASCIA, T, BONNET, P. A, LLOBELL, J, PUNZI NICOLÒ, AM, CICERO, C, CUFFARO, V, FERRI, G. B, GIACOBBE, G, GRANATA, R, MAZZAMUTO, S, RESCIGNO, P, SCARSELLI, G, SCOZZAFAVA, OT, TULLIO, L, VITUCCI, P, ANGELICI, C, FERRI, Gjr, GATTI, S, GUERRA, P, SANTONASTASO, F, SCOGNAMIGLIO, G, TERRANOVA, G, CAPONI, R, MARENGO, R, MONTERO AROCA, J, RAMOS MÉNDEZ, F, STÜRNER, R, TROCKER, N, VELLANI, C, WALTER, G, WOPERA, Z, CARDIA, C, DALLA TORRE ,G, PICOZZA, P, APICE, U, CASTAGNOLA, A, COLESANTI, V, D’ALESSANDRO, F, FERRI, C, FRASCAROLI SANTI, E, LASCARO, P, MELUCCO, A, NORELLI, E, SCALERA, I, VONA, G, PESSI, R, RAMACCI, F, FERCIA, R, SCHIPANI, S, BERLINGUER, A, BIAVATI, P, GHIA, L, LUPOI, MA, PROTO, V, CAPRIOLI, S, CARCATERRA, G, D’ADDIO, M, DE SANCTIS, FM, IRTI, N, NASI, A, PACE, A, PUNZI, A, ROMANO, B., MONTELEONE, Girolamo, ZIINO, Salvatore, Fazzalari, E (presidente comitato promotore), Bongiorno, G (coordinatore), Monteleone, G (coordinatore), Ruffini, G(coordinatore), ACONE, M, ANDOLINA, IA, AULETTA, F, BALENA, G, BASILICO, G, CAVALLINI, C, CAVALLONE, B, CHIZZINI, A, COMOGLIO, LP, CORSINI, F, DI CARLO, G, DITTRICH, L, GIORGETTI, M, GIOVANNUCCI ORLANDI, C, GIUSSANI, A, GUARNIERI, G, IMPAGNATIELLO, G, LA CHINA, S, LANFRANCHI, L, MENCHINI, S, MONTELEONE, G, PETRELLA, V, PICARDI, N, RUFFINI, G, SANDULLI, P, SOTGIU, N, TRISORIO LIUZZI, G, VALENTINI, S, CAPPONI, B, GRAZIOSI, A, IANNICELLI, L, MACCARRONE, R, NERI, A, PROTO PISANI, A, CORDOPATRI, F, LAZZARA, G, TESORIERE, G, VACCARELLA, R, VELLANI, M, CHIARLONI, S, COSTANTINO, G, DI FABIO, M, PAGNI, I, SASSANI, B, SCALA, A, BERNARDINI, P, BERTOLDI, V, BOCCAGNA, S, BORGHESI, D, BOVE, M, CANALE, G, CARPI, F, CONSOLO, C, DANOVI, F, FAZZALARI, E, GROSSI, D, LUBRANO, F, MARINELLI, M, MARINUCCI, E, NELA, PL, PICOZZA, E, RAVIDÀ, F, RICCI, EF, RICCI, GF, RIGHETTI, E, SEATZU, F, TAMPONI, M, TAVORMINA, V, VERDE, G, VIGORITI, V, ZUCCONI GALLI FONSECA, E, BRIGUGLIO, A, CARRATTA, A, DALFINO, D, GRADI, M, MARTINO, R, OLIVIERI, G, PICCININNI, L, POLI, R, RASCIO, N, RINALDI, S, RUGGERI, E, TROIANO, R, VITRÒ, V, CIPRIANI, F, D’ALESSIO, A, DALMOTTO, E, DELLA PIETRA G, LUISO, FP, NARDO, GN, PROSPERETTI, G, QUERZOLA, L, TOMMASEO, F, VULLO, E, BONGIORNO, G, CORRADO, C, DE SANTIS, F, FABIANI, M, FINOCCHIARO, G, FARINA, P, LIGUORI, G, MANCUSO, C, MONTANARI, M, NICÒTINA, G, ORIANI ,R, RECCHIONI, S, SALETTI, A, ZIINO, S, DE ROBERTO, A, FANTOZZI, A, ODORISIO, E, SCOCA, F G, VIOLANTE, V, LIBERTINI, M, MURRA, R, RENZETTI, F, RESTA, D, SCIASCIA, T, BONNET, P A, LLOBELL, J, PUNZI NICOLÒ, AM, CICERO, C, CUFFARO, V, FERRI, G B, GIACOBBE, G, GRANATA, R, MAZZAMUTO, S, RESCIGNO, P, SCARSELLI, G, SCOZZAFAVA, OT, TULLIO, L, VITUCCI, P, ANGELICI, C, FERRI, Gjr, GATTI, S, GUERRA, P, SANTONASTASO, F, SCOGNAMIGLIO, G, TERRANOVA, G, CAPONI, R, MARENGO, R, MONTERO AROCA, J, RAMOS MÉNDEZ, F, STÜRNER, R, TROCKER, N, VELLANI, C, WALTER, G, WOPERA, Z, CARDIA, C, DALLA TORRE ,G, PICOZZA, P, APICE, U, CASTAGNOLA, A, COLESANTI, V, D’ALESSANDRO, F, FERRI, C, FRASCAROLI SANTI, E, LASCARO, P, MELUCCO, A, NORELLI, E, SCALERA, I, VONA, G, PESSI, R, RAMACCI, F, FERCIA, R, SCHIPANI, S, BERLINGUER, A, BIAVATI, P, GHIA, L, LUPOI, MA, PROTO, V, CAPRIOLI, S, CARCATERRA, G, D’ADDIO, M, DE SANCTIS, FM, IRTI, N, NASI, A, PACE, A, PUNZI, A, and ROMANO, B

Subjects
natura giuridica del titolo esecutivo, Settore IUS/15 - Diritto Processuale Civile, esecuzione diretta, opposizione
Published
2008

26. L'IMPRESA E LE SOCIETA'

Author

MAZZAMUTO, Salvatore, LIBERTINI M, ANGELICI C., AAVV, MAZZAMUTO S, CASTRONOVO C, Mazzamuto, Salvatore, Libertini, M, and Angelici, C.

Published
2007

28. La Somministrazione

Author

Nova, G, Libertini, M, Denozza, F, Vettori, G, Pardolesi, R, Carnevali, U, Angelici, C, Fondireschi, A, Romeo, C, Rizzi, A, Federico, A, Capo, G, D'Adda, A, Cristofaro, G, Monticelli, S, Rosa, G, Merli, M, Villa, G, Camilleri, E, Motti, C, Macario, F, Navaretta, E, Bozzi, L, D'Amico, G, and Raimo, R

Subjects
Settore IUS/01 - Diritto Privato, contratto di somministrazione, concorrenza tra imprese
Published
2012

37. Brevi considerazioni in tema di impresa e società

Author

Tesauro, G, Teubner, G, Femia, P, Monateri, Pier, G, Mattei, U, Scalisi, V, Bile, F, Rodota', S, Franzoni, M, Carusi, D, Gentili, A, DEL PRATO, E, Orlandi, M, Velluzzi, V, Benedetti, G, Conte, G, Addis, F, Cesaro, E, Navarretta, E, Padovini, F, Polidori, S, Alvosi, C, Galgano, F, Libertini, M, Ricciuto, V, Trimarchi, M, Maugeri, Mr, Meli, V, Weigman, R, Abbriani, N, Ferri, G, STELLA RICHTER, Mjr, Tizzano, A, Busnelli, Fd, Gorassini, A, Zoppini, A, Barcellona, M, Lipari, N, Consolo, C, Alpa, G, and Perlingieri, P

Subjects
Settore IUS/04 - Diritto Commerciale
Published
2010

43. Systemic Therapy in Perivascular Epithelioid Cell Tumors (Pecoma)

Author

Hindi, N., primary, Sanfilippo, R., additional, Stacchiotti, S., additional, Fumagalli, E., additional, Libertini, M., additional, Provenzano, S., additional, Palassini, E., additional, Bertulli, R.M., additional, Marrari, A., additional, Galli, L., additional, Formica, V., additional, Chiuri, V.E., additional, Natale, D., additional, Collini, P., additional, Dei Tos, A.P., additional, and Casali, P.G., additional

Published
2014
Full Text
View/download PDF

44. Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-à-vis Temozolomide and Antiangiogenics

Author

Stacchiotti, S., primary, Tortoreto, M., additional, Bozzi, F., additional, Tamborini, E., additional, Morosi, C., additional, Messina, A., additional, Libertini, M., additional, Palassini, E., additional, Cominetti, D., additional, Negri, T., additional, Gronchi, A., additional, Pilotti, S., additional, Zaffaroni, N., additional, and Casali, P.G., additional

Published
2013
Full Text
View/download PDF

46. Response to Chemotherapy in Solitary Fibrous Tumor

Author

Stacchiotti, S., primary, Libertini, M., additional, Palassini, E., additional, Negri, T., additional, Fatigoni, S., additional, Poletti, P., additional, Vincenzi, B., additional, De Tos, A.P.I., additional, Pilotti, S., additional, and Casali, P.G., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results